Slide 1: Q1 2026 earnings
Q1 2026 earnings Chloe Podder since 2021 May 6, 2026 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, source or third-party suppliers on which we are dependent; failure to retain key future operating and financial performance, product success and efficacy, the outcome suppliers; challenges to t
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company’s performance, and the • Constant currency revenue growth, which represents th
Slide 4: Q1 2026 performance
Q1 2026 performance Total revenue Omnipod revenue by geography Other financial highlights U.S. Omnipod A D JU S T E D $515.6M O P ER AT IN G M A RG IN 1 28.3% 17.5% Total Company Total Omnipod $761.7M $758.4M up 110 bps 33.9%, 36.9%, A D JU S T E D 30.1% constant currency1 33.0% constant currency1 E
Slide 5: Progress against our strategic objectives
Progress against our strategic objectives Grew global customer base by nearly 25% YoY, driven by continued demand for Omnipod 5 in our established and newly launched geographies ATTD Highlights: • Presented data on new Omnipod 5 algorithm update, adding greater personalization and an enhancement to
Slide 6: Key commercial metrics
Key commercial metrics5 Outpaced FY2025 Delivered Q1 category revenue growth NCS growth of ~20% driven by outperformance6 YoY in U.S. & international in both the U.S. & international Over Over Over 85% U.S. NCS from 95% U.S. customer base 65% International MDI in Q1 with Omnipod 5 in Q1 customer bas
Slide 7: FY 2026 guidance
FY 2026 guidance7 Revenue guidance8 P&L guidance Assumptions & drivers Q2 2026 FY 2026 FY 2026 adjusted FY 2026 adjusted Continued strong Omnipod 5 revenue revenue operating margin9 EPS growth9 adoption globally ~100bps >25% U.S. & International annual 20% - 22% 21% - 23% NCS growth YoY (Previously
Slide 8: Thank you
Thank you 8
Slide 9: Appendix
Appendix 9
Slide 10: Insulet common abbreviations and acronyms
Insulet common abbreviations and acronyms A1C Blood test measures average blood glucose levels over the last 3 months HCP Health Care Provider ADA American Diabetes Association iOS iPhone Operating System AID Automated Insulin Delivery KOL Key Opinion Leader ASP Average Selling Price LMR Limited Mar
Slide 11: Q1 2026 financial performance
Q1 2026 financial performance $s in Millions Total Revenue10 Total Omnipod10 Adjusted Gross Profit & Margin 11 U.S. Omnipod International Omnipod9 Adjusted Operating Income & Margin 11 11 11
Slide 12: Historical financial performance
Historical financial performance $s in Millions Total Revenue10 Total Omnipod10 Gross Profit & Margin 11 11 U.S. Omnipod International Omnipod10 Operating Income & Margin 11 11 11 12
Slide 13: Non-GAAP reconciliation — revenue guidance
Non-GAAP reconciliation — revenue guidance Year Ending December 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 20% to 22% —% 20% to 22% International Omnipod 29% to 31% 3% 26% to 28% Total Omnipod 23% to 25% 1% 22% to 24% Drug Delivery ~(50)% —% ~(50)% Total Revenue 22%
Slide 14: Reconciliation of historical non-GAAP measures
Reconciliation of historical non-GAAP measures $s in Millions FY2025 % of FY2024 % of FY2023 % of FY2022 % of Q1 2026 % of Q1 2025 % of Revenue Revenue Revenue Revenue Revenue Revenue Total Revenue GAAP Growth Rate 30.7 % 22.1 % 30.0 % 18.8 % 33.9 % 28.8 % Less: Currency Impact 1.2 % 0.2 % 0.4 % (3.
Slide 15: Reconciliation of historical non-GAAP measures
Reconciliation of historical non-GAAP measures FY2025 FY2024 FY2023 FY2022 Q1 2026 Q1 2025 GAAP Diluted EPS $ 3.48 $ 5.78 $ 2.94 $ 0.07 $ 1.30 $ 0.50 Voluntary MDCsa — — (0.16) 0.83 0.13 — Legal Costsb — — — 0.36 — — CEO and CFO Transition Costsc (0.04) — — 0.05 — — Loss (Gain) on Investmentsd 0.08
Slide 16: Endnotes
Endnotes Page Title Marker Footnote 4,5 Q1 2026 performance, 1 Growth rates are on a YoY basis. Constant Currency, adjusted operating margin and adjusted earnings per share are Progress against our strategic objectives non-GAAP measures. See description of non-GAAP financial measures contained in th